FY2027 EPS Estimates for AC Immune Cut by HC Wainwright

Key Points

• HC Wainwright has reduced its FY2027 earnings per share (EPS) estimate for AC Immune from $0.12 to $0.10, maintaining a "Buy" rating with a price objective of $12.00.
• AC Immune reported a quarterly EPS of (0.25), missing estimates, and revenue of $1.65 million, which was below analyst expectations of $1.98 million.
• Institutional investors now hold 51.36% of AC Immune stock, with several new positions acquired recently, indicating growing institutional interest in the company.

AC Immune (NASDAQ:ACIU - Free Report) - Stock analysts at HC Wainwright lowered their FY2027 earnings per share (EPS) estimates for AC Immune in a research note issued to investors on Wednesday, August 6th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of $0.10 per share for the year, down from their prior estimate of $0.12. HC Wainwright currently has a "Buy" rating and a $12.00 price target on the stock. The consensus estimate for AC Immune's current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for AC Immune's FY2028 earnings at $1.27 EPS and FY2029 earnings at $1.87 EPS.

Separately, Wall Street Zen upgraded AC Immune from a "hold" rating to a "buy" rating in a research report on Tuesday, May 13th.

AC Immune Trading Up 2.9%

Shares of NASDAQ:ACIU traded up $0.06 during mid-day trading on Thursday, reaching $2.14. The stock had a trading volume of 97,918 shares, compared to its average volume of 163,494. The company has a market cap of $214.88 million, a P/E ratio of -3.69 and a beta of 1.65. AC Immune has a 1 year low of $1.43 and a 1 year high of $3.98. The business's 50 day moving average price is $2.07 and its 200 day moving average price is $2.06.

AC Immune (NASDAQ:ACIU - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.05). The firm had revenue of $1.65 million during the quarter, compared to analysts' expectations of $1.98 million. AC Immune had a negative return on equity of 49.35% and a negative net margin of 174.94%.

Institutional Investors Weigh In On AC Immune

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quinn Opportunity Partners LLC purchased a new stake in AC Immune during the fourth quarter valued at approximately $27,000. Two Sigma Advisers LP bought a new position in shares of AC Immune during the fourth quarter valued at approximately $36,000. Boothbay Fund Management LLC bought a new position in shares of AC Immune during the fourth quarter valued at approximately $38,000. Jane Street Group LLC bought a new position in shares of AC Immune during the fourth quarter valued at approximately $66,000. Finally, Cantor Fitzgerald L. P. bought a new position in shares of AC Immune during the fourth quarter valued at approximately $68,000. 51.36% of the stock is currently owned by hedge funds and other institutional investors.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.